Posted by Michael Wonder on 31 Jan 2020
Pulmatrix receives fast track designation for Pulmazole for the treatment of asthma-ABPA
30 January 2020 - Pulmatrix today announced that the U.S. FDA has granted fast track designation to PUR1900 (Pulmazole), the Company's inhaled itraconazole anti-fungal candidate being developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
Pulmatrix is currently enrolling patients in its ongoing randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety, tolerability, pulmonary function and biomarker response of Pulmazole in subjects with asthma-ABPA.
